Results 101 to 110 of about 8,326 (241)

Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39). [PDF]

open access: yes, 2017
Preclinical studies show that the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin (9-39), can reduce acute emesis induced by cisplatin. In the present study, we investigate the effect of exendin (9-39) (100 nmol/24 h, i.c.v), on cisplatin (5
Aggarwal   +74 more
core   +1 more source

Treatment for Refractory Pruritus Using Oral Aprepitant [PDF]

open access: hybrid, 2016
Joon Huh   +4 more
openalex   +1 more source

EVALUASI PENGGUNAAN ANTIEMETIKA PADA PASIEN KANKER NASOFARING DENGAN KEMOTERAPI DI INSTALASI RAWAT INAP RSUD Dr MOEWARDI SURAKARTA TAHUN 200 [PDF]

open access: yes, 2010
Penggunaan obat kemoterapi dapat menyebabkan mual dan muntah, obat kemoterapi pada kanker nasofaring merupakan obat dengan emetogenisitas tinggi dan sedang. Efek ini dapat menurunkan efektivitas penggunaan kemoterapi bila tidak ditangani dengan tepat.
RAHAYU , PRIYANTI
core  

Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Chronic inflammation in fibroblast-like synoviocytes (FLSs) induced by pro-inflammatory cytokines such as TNF-α plays a key role in the pathogenesis of rheumatoid arthritis (RA). The neurokinin-1 receptor (NK-1R) is one of the G protein–coupled receptors
Xiaoping Liu   +5 more
doaj   +1 more source

Tratamiento de la emesis inducida por citotóxicos [PDF]

open access: yes, 2004
Nausea and vomiting are important side effects of most chemotherapy anticancer drugs, since nearly two thirds of the patients under chemotherapy have this toxicity in absence of antiemetic treatment.
López, Sara, Martín, Miguel
core   +1 more source

RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE [PDF]

open access: yes, 2012
Background: Scientific data provide today the evidence that secondary K-RAS mutations do not occur during anti-EGFR therapy in CRC patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab ...
BRONTE, Giuseppe
core  

Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome [PDF]

open access: diamond, 2019
Swetha Parvataneni   +3 more
openalex   +1 more source

Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy

open access: yesEgyptian Liver Journal
Background HCC (Hepatocellular carcinoma) is the most common primary malignant cancer in the liver. Treatment options to incurable HCC such as sorafenib, an oral multikinase inhibitor, had numerous side effects and questionable effectiveness.
Heba E. Sedky   +7 more
doaj   +1 more source

Antitumor Strategies Targeting Peptidergic Systems

open access: yesEncyclopedia
Peptidergic systems show promise as targets for fighting tumors. While some peptides encourage the growth and spread of tumor cells and angiogenic mechanisms, others display antitumor properties. As such, peptide ligands and receptor antagonists could be
Francisco D. Rodríguez, Rafael Coveñas
doaj   +1 more source

Home - About - Disclaimer - Privacy